Prime Medicine's (PRME) recent financing removes a major overhang on the company's stock as it looks forward to several major upside opportunities in 2027, Oppenheimer said in a Friday note.
The company reported a Q3 loss late Thursday of $0.22 per diluted share on revenue of $4.21 million. Analysts polled by FactSet expected an EPS loss of $0.24 on revenue of $1.3 million. Prime also closed a public offering of about 41.1 million common shares at $3.50 each for gross proceeds of roughly $143.7 million.
The capital raise yields pro-forma cash, cash equivalents, investments and restricted cash of around $209.5 million, which provides a cash runway through 2027, the company said. The removal of the financing overhang that pressured the stock will encourage investors to move their focus to upcoming clinical readouts in 2027, Oppenheimer analysts said.
New draft guidance on gene editing from the US Food and Drug Administration allows certain follow-on programs to move from laboratory testing directly to a biologics license application, skipping human trials. This would expedite and lower the costs of drug development and render previously unprofitable programs viable, the analysts said.
Clinical data from the company's Wilson disease program has the potential to unlock a significant opportunity of around 8,000 US patients, the analysts said. They added that key opinion leaders expect that Prime can potentially capture a market share of 70% to 90%.
Oppenheimer reiterated the company's stock rating at outperform and price target at $11.
Price: 4.31, Change: +0.42, Percent Change: +10.67
Comments